Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Review the latest on COVID-19 vaccines.
For patients who need a mitral or aortic valve replacement, Weill Cornell Medicine’s Department of Cardiothoracic Surgery offers several surgical options, including a minimally invasive technique called percutaneous transcatheter valve replacement (TAVR or TMVR).
TAVR is a minimally invasive approach in which a surgeon threads a catheter (thin tube) up to the heart through a blood vessel in the groin to replace the damage valve. This technique makes valve replacement possible for patients who would not tolerate conventional heart surgery.
Weill Cornell Medicine and NewYork-Presbyterian are leaders in the development this surgical technique—both for mitral and aortic valve replacement. In fact, our physicians participated as investigators in two pivotal clinical trials that established the effectiveness of percutaneous (transcatheter) valve surgery:
• The EVEREST II trial evaluated the percutaneous implantation of a clip that grasps and approximates the edges of the mitral valve leaflets. The percutaneous approach was associated with superior safety and similar improvements in clinical outcomes compared with conventional surgery.
Our physicians continue to play a leading role in the clinical trials assessing the latest percutaneous mitral and aortic valve replacement approaches, giving us more experience than most centers in these emerging new techniques.
Our TAVR patients also benefit from:
• Our superior record of excellent surgical outcomes
• Our surgeons works with each patient to develop an individualized, comprehensive treatment plan
• Collaboration with other specialists (such as cardiologists and anesthesiologists) to provide seamless, high-quality care
